← Leaderboards
Koen K Van Rompay
University Of California At Davis
$14,848,913
Attributed
$14,848,913
Total exposure
31
Grants
19
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.6M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,848,913 · 31
By mechanism
P01$8,753,833 · 4
P51$2,454,441 · 23
R21$2,260,654 · 2
U42$1,379,985 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of California At Davis
Same institution · by research overlap
- Jeffrey A Roberts$8,865,937
- Michael D. George$1,323,690
- Katti Robin Crakes$125,185
- Alice F Tarantal$43,386,026
- Prasant Mohapatra$0
Others in their field
Top investigators on “Virus”
- David Heimbrook · Leidos Biomedical Research, Inc.$512,873,478
- Lawrence Corey · Fred Hutchinson Cancer Center$392,679,667
- Barton F Haynes · Duke University$328,711,626
- Dennis R. Burton · Scripps Research Institute$276,624,892
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$274,342,142
- Richard Webby · St. Jude Children'S Research Hospital$265,067,789
Research focus
VirusResourcesMacaca MulattaPrimatesAnimal ModelCommunicable DiseasesMacacaImmunologyInflammationLymphatic SystemAidsMammaliaOral PharyngealSamplingPharmacologyVaccinesNonhuman PrimateSafetyGrantDesignUnited States National Institutes Of HealthVirus DiseasesMonitorMaintenance
Grant awards (51)
Preclinical Core$1,716,552
P01 · FY2025 · AI · contact PI
Viral Testing Core$191,519
U42 · FY2025 · OD · contact PI
Viral Testing Core$192,551
U42 · FY2024 · OD · contact PI
Viral Testing Core$250,014
U42 · FY2023 · OD · contact PI
Viral Testing Core$250,013
U42 · FY2022 · OD · contact PI
Viral Testing Core$250,014
U42 · FY2021 · OD · contact PI
Immunogenicity and Efficacy of SARS-CoV-2 stabilized prefusion Spike protein vaccines in infant rhesus macaques$217,604
P01 · FY2021 · AI · contact PI
Immunogenicity and Efficacy of SARS-CoV-2 stabilized prefusion Spike protein vaccines in infant rhesus macaques$886,934
P01 · FY2020 · AI · contact PI
Viral Testing Core$245,874
U42 · FY2020 · OD · contact PI
Non-Human Primate Core (NHP Core)$733,400
P01 · FY2019 · AI · contact PI
Non-Human Primate Core (NHP Core)$1,337,754
P01 · FY2018 · AI · contact PI
Development of a nonhuman primate model of fetal Zika virus infection and disease$115,800
R21 · FY2018 · AI · contact PI
Development of a nonhuman primate model of fetal Zika virus infection and disease$1,786,954
R21 · FY2017 · AI · contact PI
Non-Human Primate Core (NHP Core)$854,320
P01 · FY2017 · AI · contact PI
Non-Human Primate Core (NHP Core)$1,260,301
P01 · FY2016 · AI · contact PI
Non-Human Primate Core (NHP Core)$686,024
P01 · FY2016 · AI · contact PI
Non-Human Primate Core (NHP Core)$1,060,944
P01 · FY2015 · AI · contact PI
COMPARE ANTIVIRAL EFFICACY OF ORALTDF & SUBCUTANEOUSTFV IN SIV-INFECTED MACAQUES$191,444
P51 · FY2011 · RR · contact PI
LONG-TERM SAFETY AND EFFICACY OF PMPA (TENOFOVIR)$191,444
P51 · FY2011 · RR · contact PI
COMPARE ANTIVIRAL EFFICACY OF ORALTDF & SUBCUTANEOUSTFV IN SIV-INFECTED MACAQUES$152,094
P51 · FY2010 · RR · contact PI
LONG-TERM SAFETY AND EFFICACY OF PMPA (TENOFOVIR)$152,091
P51 · FY2010 · RR · contact PI
COMPARE ANTIVIRAL EFFICACY OF ORALTDF & SUBCUTANEOUSTFV IN SIV-INFECTED MACAQUES$146,581
P51 · FY2009 · RR · contact PI
LONG-TERM SAFETY AND EFFICACY OF PMPA (TENOFOVIR)$146,578
P51 · FY2009 · RR · contact PI
LONG-TERM SAFETY AND EFFICACY OF PMPA (TENOFOVIR)$168,992
P51 · FY2008 · RR · contact PI
ROLE OF CD8+ CELLS ON SIVMAC1A11 REPLICATION$181,571
P51 · FY2007 · RR · contact PI
LONG-TERM SAFETY AND EFFICACY OF PMPA (TENOFOVIR)$181,569
P51 · FY2007 · RR · contact PI
LONG-TERM SAFETY AND EFFICACY OF PMPA (TENOFOVIR)$156,653
P51 · FY2006 · RR · contact PI
TOPICAL VIRUCIDES TO PREVENT ORAL TRANSMISSION$156,653
P51 · FY2006 · RR · contact PI
ROLE OF CD8+ CELLS ON SIVMAC1A11 REPLICATION$99,319
P51 · FY2006 · RR · contact PI
TOPICAL VIRUCIDES TO PREVENT ORAL TRANSMISSION$207,141
P51 · FY2005 · RR
LONG-TERM SAFETY AND EFFICACY OF PMPA (TENOFOVIR)$207,141
P51 · FY2005 · RR
Topical virucides to prevent oral transmission$178,950
R21 · FY2004 · AI
LONG-TERM SAFETY AND EFFICACY OF PMPA (TENOFOVIR)$17,353
P51 · FY2004 · RR
Topical virucides to prevent oral transmission$178,950
R21 · FY2003 · AI
LONG-TERM SAFETY AND EFFICACY OF PMPA (TENOFOVIR)$97,817
P51 · FY2003 · RR
TWO DOSES OF PMPA PROTECT NEWBORN MACAQUES AGAINST ORAL SIV INFECTION$0
P51 · FY2002 · RR
TWO DOSES OF PMPA PROTECT NEWBORN MACAQUES AGAINST ORAL SIV INFECTION$0
P51 · FY2002 · RR
SINGLE DOSE PMPA POST EXPOSURE PROPHYLAXIS AGAINST SIV INFECTION$0
P51 · FY2002 · RR
PMPA THERAPY OF PEDIATRIC AIDS$0
P51 · FY2002 · RR
PATHOGENESIS OF ORAL SIVMAC055 INFECTION IN JUVENILE MACAQUES$0
P51 · FY2002 · RR
IMMUNOMODULATORY EFFECTS OF PMPA IN RHESUS MACAQUES$0
P51 · FY2002 · RR
LOW DOSE PMPA POST EXPOSURE PROPHYLAXIS AGAINST SIV IN NEWBORN MACAQUES$0
P51 · FY2002 · RR
PMPA PROPHYLAXIS OF SIV INFECTION IN NEWBORN MACAQUES$0
P51 · FY2002 · RR
TWO DOSES OF PMPA PROTECT NEWBORN MACAQUES AGAINST ORAL SIV INFECTION$0
P51 · FY2001 · RR
TWO DOSES OF PMPA PROTECT NEWBORN MACAQUES AGAINST ORAL SIV INFECTION$0
P51 · FY2001 · RR
SINGLE DOSE PMPA POST EXPOSURE PROPHYLAXIS AGAINST SIV INFECTION$0
P51 · FY2001 · RR
PMPA THERAPY OF PEDIATRIC AIDS$0
P51 · FY2001 · RR
PATHOGENESIS OF ORAL SIVMAC055 INFECTION IN JUVENILE MACAQUES$0
P51 · FY2001 · RR
IMMUNOMODULATORY EFFECTS OF PMPA IN RHESUS MACAQUES$0
P51 · FY2001 · RR
LOW DOSE PMPA POST EXPOSURE PROPHYLAXIS AGAINST SIV IN NEWBORN MACAQUES$0
P51 · FY2001 · RR
PMPA PROPHYLAXIS OF SIV INFECTION IN NEWBORN MACAQUES$0
P51 · FY2001 · RR